Laboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
Chem Biol Drug Des. 2018 Mar;91(3):668-680. doi: 10.1111/cbdd.13131. Epub 2017 Nov 16.
G-protein-coupled receptor 40 (GPR40) was recently identified as an interesting target for treatment of type 2 diabetes. The high level of expression in pancreatic beta cells and the dependence of glucose on stimulating the secretion of insulin led to great excitement in this field. The identification of this target was followed by the development of a series of agonists with great potential for the treatment of diabetes. All known agonists have the presence of a pharmacophoric carboxylic acid group in their structure, which makes several polar interactions at the binding site of this receptor. In this report, we provide a review of the structure-activity relationships of GPR40 agonists with a focus on the main strategies of medicinal chemistry used to develop each one of the main structural patterns exploited for this purpose. Additionally, we provide a general model for the design of GPR40 ligands that can help researchers to follow up some strategies and implement them in the development of novel agonists of this receptor.
G 蛋白偶联受体 40(GPR40)最近被确定为治疗 2 型糖尿病的一个有前途的靶点。它在胰腺β细胞中的高表达水平以及对葡萄糖刺激胰岛素分泌的依赖性,在该领域引起了极大的关注。该靶点的鉴定随后引发了一系列具有治疗糖尿病巨大潜力的激动剂的开发。所有已知的激动剂在其结构中都存在一个药效团羧酸基团,这使得该受体的结合部位存在多个极性相互作用。在本报告中,我们对 GPR40 激动剂的构效关系进行了综述,重点介绍了用于开发为此目的而利用的主要结构模式的每个模式的药物化学的主要策略。此外,我们还提供了一个 GPR40 配体设计的一般模型,该模型可以帮助研究人员跟踪一些策略,并将其应用于该受体的新型激动剂的开发中。